MedTrace Logo

Special Drug Use Observational Study With Beovu Kit for Intravitreal Injection

NCT05526729 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 222

Last updated 2025-06-13

No results posted yet for this study

Summary

This was a primary data collection-based observational special drug-use surveillance to be conducted in accordance with the Good Post-marketing Study Practice (GPSP) ordinance.

Conditions

Interventions

OTHER

Beovu

Prospective observational study. There was no treatment allocation. Patients prescribed with Beovu for the first time for diabetic macular edema were eligible to enroll into this study.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
0 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-02
Primary Completion
2024-06-29
Completion
2024-06-29

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05526729 on ClinicalTrials.gov